Online inquiry

IVTScrip™ mRNA-Anti-IL23A, BI 655066(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4029MR)

This product GTTS-WQ4029MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL23A gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_016584.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 51561
UniProt ID Q9NPF7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL23A, BI 655066(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ4029MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15595MR IVTScrip™ mRNA-Anti-SLC29A2, VAL-1221(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA VAL-1221
GTTS-WQ13333MR IVTScrip™ mRNA-Anti-PDCD1, PF-06801591(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PF-06801591
GTTS-WQ13774MR IVTScrip™ mRNA-Anti-MSTN, REGN-1033(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA REGN-1033
GTTS-WQ3805MR IVTScrip™ mRNA-Anti-NCAM1, BB-10901(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BB-10901
GTTS-WQ2437MR IVTScrip™ mRNA-Anti-TSLP, AMG 157(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 157
GTTS-WQ8750MR IVTScrip™ mRNA-Anti-TNFRSF4, IBI-101(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IBI-101
GTTS-WQ7370MR IVTScrip™ mRNA-Anti-FZD7, FZD8-Fc(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA FZD8-Fc
GTTS-WQ3599MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1129980(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BAY 1129980
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW